Edgewise Therapeutics, Inc.
EWTXNASDAQ
USReal-Time Price
USReal-Time Price$37.68USD
-0.43 (-1.13%)Today
$37.85+0.17 (+0.45%)Pre-MarketLast quote · Nov 4, 2026, 7:31 AM ET
BTI Score
BASIC required or higher
View pricingBTI Fair Market Cap
$517.53M
+690.72% vs fair
Biotechnology
High Risk
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
BTI's proprietary analysis of Edgewise Therapeutics, Inc. (EWTX): overall score, long- and short-term outlook, risk rating and fair-value verdict based on fundamentals, valuation and momentum.
Major-Firm Consensus
Strong Buy
Filtered to 19 major global investment banks
Buy
17
Hold
2
Sell
0
Price Target Consensus
High
$66.00
Consensus
$54.00
Low
$36.00
Current
$37.68
Upside: +43.3%
Target Trend
Last Month— (0)
Last Quarter— (0)
Last Year— (0)
Ratings History — Major Investment Banks
| Firm | Rating | Action | Previous | Price Target | Upside | Date |
|---|---|---|---|---|---|---|
| RBC Capital | Buy | Maintains | — | $59.00 | +56.6% | Oct 27, 2026 |
| William Blair | Buy | Initiates | — | $53.00 | +40.7% | Oct 16, 2026 |
| H.C. Wainwright | Buy | Maintains | — | $57.00 | +51.3% | Oct 14, 2026 |
| Piper Sandler | Buy | Maintains | — | $51.00 | +35.4% | Oct 13, 2026 |
| Wedbush | Buy | Maintains | — | $53.00 | +40.7% | Sep 23, 2026 |
| Truist Financial | Buy | Reiterates | — | — | — | Sep 23, 2026 |
| Goldman Sachs | Hold | Maintains | — | $36.00 | -4.5% | Sep 23, 2026 |
| Leerink Partners | Buy | Reiterates | — | — | — | Sep 23, 2026 |
Annual Analyst Estimates
| Fiscal Year | Revenue Avg | Revenue Range | EPS Avg | EPS Range | Analysts |
|---|---|---|---|---|---|
| FY 2026 | — | — – — | $2.27 | — – — | — |
| FY 2027 | $31.4M | — – — | — | — – — | — |
Want deeper AI-powered analysis?
Get BTI AI's full investment thesis, valuation models, and risk assessment for EWTX.